The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II drugs for Pheochromocytoma have a 33% phase transition ...

BACKGROUND: There are limitations to currently available biochemical tests for pheochromocytoma. Our objective was to evaluate the diagnostic efficacy of a novel tandem mass spectrometry assay for ...

What Is Duchenne Muscular Dystrophy? Muscular dystrophies are a group of diseases that make muscles weaker and less flexible over time. Duchenne muscular dystrophy (DMD) is the most common type.

Family history or certain types of symptom profiles might indicate to a doctor that a pheochromocytoma may be present. These tumors are also linked to certain, rare genetic conditions. Diagnosis ...

Spear and Griswald 9 reported the first case of a fall in blood pressure after the administration of dibenamine (N, N-dibenzyl-β-chloroethylamine) to a patient who proved at operation to have a ...

The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma should only be initiated if the clinical evidence for the presence of tumor is reasonably ...